Tags

Type your tag names separated by a space and hit enter

Recurrence rate of hirsutism after 3 different antiandrogen therapies.
J Am Acad Dermatol. 1999 Jul; 41(1):64-8.JA

Abstract

BACKGROUND

Although antiandrogens are frequently and successfully used to treat hirsutism, little attention has been paid to optimal duration of treatment and recurrence rate after cessation of therapy.

OBJECTIVE

Our purpose was to determine the recurrence rate of hirsutism after 3 different antiandrogen therapies.

METHODS

Eighty-one hirsute women referred to a tertiary hirsutism clinic were assigned to one of three regimens: spironolactone 100 mg/day with an oral contraceptive, cyproterone acetate 50 mg/day on days 1 to 10 with an oral contraceptive, or flutamide 250 mg twice a day. Hirsutism scores according to the Ferriman-Gallwey scoring system and endocrine parameters were evaluated before, during, and 1 year after withdrawal of treatment regimens.

RESULTS

Hirsutism scores decreased significantly and similarly in spironolactone, flutamide, and cyproterone acetate treatment groups. However, 1 year after withdrawal of treatment in all antiandrogen therapy groups, hirsutism returned.

CONCLUSION

Antiandrogens are effective in the treatment of hirsutism. However, cessation of antiandrogen therapy is followed by recurrence.

Authors+Show Affiliations

Department of Dermatology, Marmara University School of Medicine, Istanbul, Turkey.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Controlled Clinical Trial
Journal Article

Language

eng

PubMed ID

10411413

Citation

Yücelten, D, et al. "Recurrence Rate of Hirsutism After 3 Different Antiandrogen Therapies." Journal of the American Academy of Dermatology, vol. 41, no. 1, 1999, pp. 64-8.
Yücelten D, Erenus M, Gürbüz O, et al. Recurrence rate of hirsutism after 3 different antiandrogen therapies. J Am Acad Dermatol. 1999;41(1):64-8.
Yücelten, D., Erenus, M., Gürbüz, O., & Durmuşoğlu, F. (1999). Recurrence rate of hirsutism after 3 different antiandrogen therapies. Journal of the American Academy of Dermatology, 41(1), 64-8.
Yücelten D, et al. Recurrence Rate of Hirsutism After 3 Different Antiandrogen Therapies. J Am Acad Dermatol. 1999;41(1):64-8. PubMed PMID: 10411413.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Recurrence rate of hirsutism after 3 different antiandrogen therapies. AU - Yücelten,D, AU - Erenus,M, AU - Gürbüz,O, AU - Durmuşoğlu,F, PY - 1999/7/20/pubmed PY - 1999/7/20/medline PY - 1999/7/20/entrez SP - 64 EP - 8 JF - Journal of the American Academy of Dermatology JO - J Am Acad Dermatol VL - 41 IS - 1 N2 - BACKGROUND: Although antiandrogens are frequently and successfully used to treat hirsutism, little attention has been paid to optimal duration of treatment and recurrence rate after cessation of therapy. OBJECTIVE: Our purpose was to determine the recurrence rate of hirsutism after 3 different antiandrogen therapies. METHODS: Eighty-one hirsute women referred to a tertiary hirsutism clinic were assigned to one of three regimens: spironolactone 100 mg/day with an oral contraceptive, cyproterone acetate 50 mg/day on days 1 to 10 with an oral contraceptive, or flutamide 250 mg twice a day. Hirsutism scores according to the Ferriman-Gallwey scoring system and endocrine parameters were evaluated before, during, and 1 year after withdrawal of treatment regimens. RESULTS: Hirsutism scores decreased significantly and similarly in spironolactone, flutamide, and cyproterone acetate treatment groups. However, 1 year after withdrawal of treatment in all antiandrogen therapy groups, hirsutism returned. CONCLUSION: Antiandrogens are effective in the treatment of hirsutism. However, cessation of antiandrogen therapy is followed by recurrence. SN - 0190-9622 UR - https://www.unboundmedicine.com/medline/citation/10411413/Recurrence_rate_of_hirsutism_after_3_different_antiandrogen_therapies_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0190-9622(99)70408-1 DB - PRIME DP - Unbound Medicine ER -